Mode
Text Size
Log in / Sign up

Nine patients with PPFE and DGUOK-associated mitochondriopathy show specific genetic and cellular findings.

Nine patients with PPFE and DGUOK-associated mitochondriopathy show specific genetic and cellular fi…
Photo by National Cancer Institute / Unsplash
Key Takeaway
Consider genetic testing for DGUOK variants in all patients with PPFE of unknown origin.

This publication reviews data from nine patients aged 5 to 36 years with pleuroparenchymal fibroelastosis (PPFE) and DGUOK-associated mitochondriopathy. The study characterizes the clinical, radiological, histopathological, and genetic features of this rare condition. No active intervention was performed as this is an observational case series.

All patients presented with progressive dyspnea, weight loss, and some experienced spontaneous pneumothoraces. Chest computed tomography and lung biopsies confirmed features consistent with PPFE in all nine patients. Genetic analysis identified biallelic pathogenic DGUOK variants in 9 of 9 patients. Additionally, seven of the nine patients carried an unreported intronic variant leading to mitochondrial DNA depletion.

Single-nucleus RNA sequencing (snRNAseq) was performed on four pediatric patients. These analyses identified aberrant basaloid cells and intermediate cells as precursors localized at the fibrotic edge. Mitochondrial alterations and mtDNA content were also assessed as secondary outcomes. No adverse events, discontinuations, or tolerability data were reported due to the observational design.

Detailed descriptions of pulmonary manifestations with late-onset presentation have not been previously reported. Pulmonary involvement in this context may be underrecognized or misinterpreted. This study represents the first demonstration of aberrant basaloid cells in pediatric fibrotic lung tissue. Given the association between PPFE in children and young adults and DGUOK-related mitochondriopathy, genetic testing is recommended for all patients with PPFE of unknown origin.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
BackgroundPleuroparenchymal fibroelastosis (PPFE) is a rare, fibrotic lung disease with poor prognosis, usually affecting adults which most commonly occurs idiopathically. Biallelic pathogenic variants in DGUOK cause mitochondrial DNA (mtDNA) depletion syndrome, predominantly affecting infants with severe hepatic and neurological symptoms. Detailed description of pulmonary manifestations with late-onset presentation have not been reported. MethodsWe describe nine patients with PPFE and DGUOK-associated mitochondriopathy. Clinical, radiological, histopathological, and genetic data were systematically collected from all patients. Functional studies, single nucleus RNA sequencing (snRNAseq), immunofluorescence staining, transmission electron microscopy and respiratory chain enzyme activity assays were conducted on patient-derived fibroblasts, muscle or lung tissues. mtDNA content quantification was performed on whole genome sequencing (WGS) data. ResultsAll patients (ages 5-36) presented with progressive dyspnea, weight loss and some with spontaneous pneumothoraces. Chest computed tomography and lung biopsies showed features of PPFE. Biallelic pathogenic DGUOK variants were identified in all patients, seven of them carry an unreported intronic variant leading to mtDNA depletion. snRNAseq of lung tissue from four pediatric patients identified Aberrant Basaloid cells and intermediate cells as their precursor localized at the fibrotic edge. Mitochondrial alterations were identified by electron microscopy. ConclusionPPFE in children and young adults is associated with DGUOK-related mitochondriopathy. For the first time, we demonstrate Aberrant Basaloid cells in pediatric fibrotic lung tissue. Since pulmonary involvement may be underrecognized or misinterpreted and the clinical presentation may not always be typical of a mitochondriopathy, we recommend genetic testing in all patients with PPFE of unknown origin.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.